Codexis Inc. (NASDAQ:CDXS) shares saw an uptick in trading volume on Monday . 189,370 shares were traded during mid-day trading, an increase of 70% from the previous session’s volume of 111,093 shares.The stock last traded at $4.20 and had previously closed at $4.28.

A number of research firms recently commented on CDXS. Zacks Investment Research upgraded Codexis from a “sell” rating to a “hold” rating in a report on Wednesday, August 10th. HC Wainwright began coverage on Codexis in a report on Wednesday, June 1st. They issued a “buy” rating and a $6.00 price objective on the stock.

The company has a 50-day moving average price of $4.16 and a 200-day moving average price of $3.81. The stock’s market cap is $172.96 million.

Codexis (NASDAQ:CDXS) last announced its quarterly earnings data on Tuesday, August 9th. The company reported $0.12 EPS for the quarter, topping the Zacks’ consensus estimate of $0.03 by $0.09. The firm earned $16 million during the quarter, compared to analyst estimates of $15.10 million. During the same quarter in the previous year, the business earned ($0.14) earnings per share. Codexis’s revenue for the quarter was up 166.7% compared to the same quarter last year. Analysts expect that Codexis Inc. will post ($0.21) EPS for the current fiscal year.

In other news, major shareholder Ventures Fund Vii L.P. Vivo sold 80,000 shares of the business’s stock in a transaction dated Thursday, August 4th. The stock was sold at an average price of $4.22, for a total transaction of $337,600.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Codexis, Inc is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.